alexa MicroRNAs as Essential Components of Non-Coding Genome are Emerging Key Players of Oncogenesis | OMICS International
ISSN: 2168-9547
Molecular Biology: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

MicroRNAs as Essential Components of Non-Coding Genome are Emerging Key Players of Oncogenesis

Mustafa Ozen1,2* and Omer Faruk Karatas1,3

1Department of Medical Genetics, Istanbul University Cerrahpasa Medical School, Istanbul, Turkey

2Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, 77030, USA

3Molecular Biology and Genetics Department, Erzurum Technical University, Erzurum, Turkey

Corresponding Author:
Mustafa Ozen
Istanbul University, Cerrahpasa Medical School
Department of Medical Genetics
Fatih, Istanbul, Turkey
Tel: +90 212-414-3000-21304
Fax: +90 212-414-3184
E-mail: [email protected]

Received date: October 01, 2013; Accepted date: October 02, 2013; Published date: October 07, 2013

Citation: Ozen M, Karatas OF (2013) MicroRNAs, as Essential Components of Non-Coding Genome, are Emerging Key Players of Oncogenesis. Mol Biol 2:e112. doi:10.4172/2168-9547.1000e112

Copyright: © 2013 Ozen M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Molecular Biology: Open Access

Abstract

miRNA expression profiling remains very crucial for understanding the underlying mechanisms of cancer initiation, progression, invasion or metastasis and developing novel and promising therapeutic applications against cancer. Meanwhile, further studies elucidating miRNAs’ mechanisms of action are necessary to
shed light on how miRNAs function in cancer pathogenesis and to overcome the putative challenges like side effects and problems in delivery to their right targets.

MicroRNAs (miRNAs) were originally identified in 1993, when a non-coding small RNA gene, lin-4, has been discovered in a genetic screen utilized to find out genes controlling developmental timing of the nematode, Caenorhabditis elegans larvae [1,2]. Findings about lin-4 and other newly discovered small non-coding RNAs having the capacity to alter gene expression post-transcriptionally in a variety of species including mammalians, put forward miRNAs, which, are endogenously synthesized, approximately 22 nucleotide-long, single stranded and non-coding RNAs, as indispensable components of noncoding genome [3-6]. Since their discovery, hundreds of miRNAs have been shown to play essential roles through modulating expression of their validated targets in several biological events both in physiological and pathological conditions [7-9] and they are estimated to regulate the expression of at least 60% of human genes [10].

MiRNAs have become a very popular subject in cancer research field, since Calin et al. showed the association between miRNAs and cancer for the first time as a result of identifying miR-15-a and miR-16- 1 as localized on a chromosomal region, which is frequently deleted in B-cell chronic lymphocytic leukemia cases [11]. Since then, remarkable achievements have been accomplished concerning miRNAs and their involvement in pathogenesis of distinct cancer types. They has been shown to have either oncogenic or tumor suppressor potential. Recently, among many others, miR-125b, miR-221/222, miR-21, miR-27a and miR-106a are implicated as key oncogenic miRNAs associated with tumorigenesis [12]. Besides, miR-145, miR-34c, and let-7c are known as the most known tumor suppressor miRNAs in carcinogenesis. In addition to their oncogenic and tumor suppressor potencies, miRNAs are reported to be associated with tumor progression and metastasis. Although functions of miRNAs in these processes still remain to be resolved, in distinct cancers, certain miRNAs such as let7c, miR-21, miRr-34a, miR-145 and miR-205 have been implicated as significant effectors in cell migration and metastatic pathways [13-17].

Furthermore, due to several advantages such as not being complex, having no posttranscriptional modification, easy detection of expressional changes, having tissue, body fluid specific profile, being highly conserved amongst human and other model organisms, and their high stability, mature miRNAs are among the ideal candidate biomarkers for characterization of physio-pathological conditions including cancer prognosis. For instance, recently miR-221 in hepatocellular carcinoma has been demonstrated to be associated with prognosis. Moreover, in the same study, increased miR-221 level has been reported to be correlated with tumor size, cirrhosis, tumor stage and poor prognosis [18]. In a different study, high level of miR- 181a expression was found to be associated with poor prognosis in astrocytoma and miR-181b has been proposed as a biomarker to differentiate high-grade glioblastomas from low-grade tumors [19]. Besides, Wang et al. demonstrated that levels of miR-21, miR-106a and miR-155 levels are elevated and those of miR-126, miR-199a and miR- 335 are reduced in serum and tissue samples of breast cancer patients with regard to healthy controls [20]. In prostate cancer, miR-26a, miR-195 and let-7i levels in serum were found to be higher in cancer patients compared to benign prostate hyperplasia patients. In another study deregulation of three miRNAs, miR-93, miR-106a and miR-24 in serum samples of in early stage prostate cancer patients compared to healthy controls [21].

Furthermore, knowing the fact that altered miRNA levels are observed in various tumor types and their specific deregulation pattern in distinct tumors make miRNAs come forward as putative therapeutic targets and diagnostic markers. For example, in pancreatic ductal adenocarcinoma cases, in which high levels of miR-21 has been observed, anti-miR-21 treatment resulted in inhibition of proliferation of human pancreatic ductal adenocarcinoma derived cell lines through induction of apoptosis. In addition, chemotherapeutics in combination with anti-miR-21 treatment are suggested to reduce the tumor size [22].

Now, after discovery of more than 2500 identified mature miRNAs in Homo sapiens [23], miRNA expression profiling remains very crucial for understanding the underlying mechanisms of cancer initiation, progression, invasion or metastasis and developing novel and promising therapeutic applications against cancer. Meanwhile, further studies elucidating miRNAs’ mechanisms of action are necessary to shed light on how miRNAs function in cancer pathogenesis and to overcome the putative challenges like side effects and problems in delivery to their right targets.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11611
  • [From(publication date):
    October-2013 - Dec 12, 2017]
  • Breakdown by view type
  • HTML page views : 7846
  • PDF downloads : 3765
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version